Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Bristol-Myers Squibb
BicycleTx Limited
BioNTech SE
AbbVie
Bristol-Myers Squibb
National Cancer Institute (NCI)
Bristol-Myers Squibb
Bristol-Myers Squibb
Daiichi Sankyo
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Hoffmann-La Roche
AbbVie
University of Birmingham
Hoffmann-La Roche
Second Affiliated Hospital of Nanchang University
Eikon Therapeutics
Regeneron Pharmaceuticals
Shanghai Henlius Biotech
Universitätsklinikum Hamburg-Eppendorf
Institut Curie
Bio-Thera Solutions
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Bio-Thera Solutions
Shandong New Time Pharmaceutical Co., LTD
Semmelweis University
Leiden University Medical Center
Shengjing Hospital
Shanghai Shengdi Pharmaceutical Co., Ltd
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Qilu Pharmaceutical Co., Ltd.
Polaris Group
Canadian Cancer Trials Group
Cambridge University Hospitals NHS Foundation Trust
The Netherlands Cancer Institute
National Cancer Centre, Singapore
Fudan University
ERYtech Pharma
GOG Foundation
Roswell Park Cancer Institute
Tianjin Medical University Cancer Institute and Hospital
Taizhou Hanzhong biomedical co. LTD
The Netherlands Cancer Institute
Canadian Cancer Trials Group
Institut Claudius Regaud
M.D. Anderson Cancer Center
Celgene
Velindre NHS Trust
University Hospital, Bonn
Transgene
GBG Forschungs GmbH